Veterinary Anti-infectives Market

Veterinary Anti-infectives Market Size, Share, Growth Analysis, By Animal(Livestock, Poultry), By Product(Antibacterial, Cephalosporins), By Route of Administration(Oral, Injectables), By Distribution Channel(Veterinary Clinics, Retail Pharmacies), By Region(North America, Europe) - Industry Forecast 2024-2031


Report ID: UCMIG35I2209 | Region: Global | Published Date: Upcoming |
Pages: 165 | Tables: 55 | Figures: 60

Veterinary Anti-infectives Market Insights

Market Overview:

In 2018, the global veterinary anti-infectives market reached a value of USD 5.18 billion, and it is anticipated to experience a steady compound annual growth rate (CAGR) of 6.4% throughout the forecast period. This growth can be attributed to various factors, including the increasing prevalence of infectious diseases among animals, the rising demand for animal-derived products, and the growing awareness regarding animal health and welfare. These factors are expected to drive the demand for veterinary anti-infectives globally.

Veterinary Anti-infectives Market, Forecast & Y-O-Y Growth Rate, 2020 - 2028
ForecastGrowthRate
To get more reports on the above market click here to
GET FREE SAMPLE

This report is being written to illustrate the market opportunity by region and by segments, indicating opportunity areas for the vendors to tap upon. To estimate the opportunity, it was very important to understand the current market scenario and the way it will grow in future.

Production and consumption patterns are being carefully compared to forecast the market. Other factors considered to forecast the market are the growth of the adjacent market, revenue growth of the key market vendors, scenario-based analysis, and market segment growth.

The market size was determined by estimating the market through a top-down and bottom-up approach, which was further validated with industry interviews. Considering the nature of the market we derived the Pharmaceuticals by segment aggregation, the contribution of the Pharmaceuticals in Pharmaceuticals, Biotechnology & Life Sciences and vendor share.

To determine the growth of the market factors such as drivers, trends, restraints, and opportunities were identified, and the impact of these factors was analyzed to determine the market growth. To understand the market growth in detail, we have analyzed the year-on-year growth of the market. Also, historic growth rates were compared to determine growth patterns.

Segmentation Analysis:

The Veterinary Anti-infectives Market is segmented by Animal, Product, Route of Administration, Distribution Channel, Region. We are analyzing the market of these segments to identify which segment is the largest now and in the future, which segment has the highest growth rate, and the segment which offers the opportunity in the future.

Veterinary Anti-infectives Market Basis Point Share Analysis, 2021 Vs. 2028
BasisPointShareAnalysis
To get detailed analysis on all segments
BUY NOW
  • Based on Animal the market is segmented as, Livestock, Poultry, Swine, Cattle, Sheep & Goats, Fish, Others, Companion animal, Dog, Cat, Others
  • Based on Product the market is segmented as, Antibacterial, Cephalosporins, Tetracyclines, Penicillin, Macrolides, Others (Quinoles, sulfonamides, polymyxins), Antifungals, Antivirals, Others
  • Based on Route of Administration the market is segmented as, Oral, Injectables, Others
  • Based on Distribution Channel the market is segmented as, Veterinary Clinics, Retail Pharmacies, E-commerce
  • Based on Region the market is segmented as, North America, Europe, Asia Pacific, Latin America, Middle East & Africa, KEY MARKET SEGMENTS, Zoetis, Inc., Boehringer Ingelheim GmbH, Ceva Santé Animale, Vetoquinol S.A., Merck & Co., Inc.

Regional Analysis:

Veterinary Anti-infectives Market is being analyzed by North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA) regions. Key countries including the U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, and South Africa among others were analyzed considering various micro and macro trends.

Veterinary Anti-infectives Market Attractiveness Analysis, By Region 2020-2028
AttractivenessAnalysis
To know more about the market opportunities by region and country, click here to
REQUEST FREE CUSTOMIZATION

Veterinary Anti-infectives Market : Risk Analysis

SkyQuest's expert analysts have conducted a risk analysis to understand the impact of external extremities on Veterinary Anti-infectives Market. We analyzed how geopolitical influence, natural disasters, climate change, legal scenario, economic impact, trade & economic policies, social & ethnic concerns, and demographic changes might affect Veterinary Anti-infectives Market's supply chain, distribution, and total revenue growth.

Competitive landscaping:

To understand the competitive landscape, we are analyzing key Veterinary Anti-infectives Market vendors in the market. To understand the competitive rivalry, we are comparing the revenue, expenses, resources, product portfolio, region coverage, market share, key initiatives, product launches, and any news related to the Veterinary Anti-infectives Market.

To validate our hypothesis and validate our findings on the market ecosystem, we are also conducting a detailed porter's five forces analysis. Competitive Rivalry, Supplier Power, Buyer Power, Threat of Substitution, and Threat of New Entry each force is analyzed by various parameters governing those forces.

Key Players Covered in the Report:

  • sights
  • The global veterinary anti-infectives market size was valued at USD 5.18 billion in 2018 and is expected to expand at a CAGR of 6.4% during the forecast period. The increasing awareness regarding better animal health is anticipated to drive the growth. According to a 2017 survey by the Centers for Disease Control and Prevention (CDC), approximately 48 million people get infected, 128,000 are hospitalized, and 3,000 die each year due to foodborne diseases in the U.S. Therefore, there is a rising need to curb these outbreaks with effective treatment which will further render an exponential growth for the market. Rising pressure on livestock owners to uphold the veterinary health standards to meet the demand for dairy products, fresh meat, dietary nutrition, and animal vaccines is anticipated to further speed up the adoption of veterinary anti-infectives in near future.
  • Rising pet adoption coupled with rising concerns regarding pet health and prevalence of bacterial infection, especially in dogs, is anticipated to further propel the market growth. Leptospirosis, staphylococcal infection, bacterial ear infection, actinomycosis, and nocardiosis are some of the most common forms of infections in pets. As per a report published by the Michigan Department of Agriculture and Rural Development 2018, 115 cases were recorded. Moreover, pets are susceptible to bacterial diseases, such as plague, brucellosis, and Lyme disease. According to the qualitative report by the CDC in 2018, cats are more prone to plague than dogs and can pass on the infection to humans as well.
  • The market players are investing in clinical trials of veterinary medicines, which is anticipated to bode well for the growth of the veterinary medicines market. For instance, Zoetis Inc. and Regeneron Pharmaceuticals, Inc. entered into a 5 years collaboration in June 2018, for monoclonal antibody therapeutics research to discover new animal health treatment. From this collaboration, Zoetis Inc. is licensed for Regeneron’s VelocImmune, an antibody technology for the development of monoclonal antibodies modified for species-specific use in livestock and companion animals.
  • Animal health insurance is also growing in line with the rise in livestock farming and the adoption of companion animals. Factors, such as increasing government efforts to prevent zoonosis and new product inventions are expected to exhibit a positive impact on market growth. For instance, in 2016, as per the European External Action Service (EEAS), the government invested USD 4.7 million in veterinary healthcare.
  • Animal Type Insights
  • Livestock accounted for the largest revenue share of the veterinary anti-infectives market in 2018. Livestock is sub-segmented into poultry, swine, cattle, sheep and goats, fish, and others. This segment is anticipated to witness significant growth owing to increasing meat consumption, growing daily needs, and environmental sustainability. As per the 2017 data by the North American Meat Institute, the poultry and meat industries are the largest division of the U.S. agriculture sector. This factor is anticipated to positively influence the livestock segment over the forecast period.
  • However, the companion animal segment is projected to register the fastest CAGR over the forecast period. Rising awareness regarding the health benefits associated with the adoption of small companion animals is anticipated to bode well for the growth of the segment. Some of these health benefits include decreased blood pressure, stress, anxiety, cholesterol levels, and increased psychological stability and opportunities for socialization. According to American Pet Products Association (APPA), National Pet Owners Survey 2017, households with children are three times more likely to adopt small animals as pets which leads to growing concerns as well as expenditure for veterinary healthcare needs.
  • Product Insights
  • Antibacterials segment accounted for the largest revenue share in the market for veterinary anti-infectives in 2018, owing to the rising prevalence of bacterial infections in livestock and companion animals. Major anti-bacterial, such as cephalosporins, tetracyclines, penicillins, macrolides, quinolones, sulfonamides, and polymyxins, are specifically developed for animals. The World Health Organization (WHO) engages in various activities to address health threats at the human-animal-ecosystem interface including antibacterial resistance, food-borne zoonoses, and food consumption. This is expected to drive the need for better healthcare facilities for vets and demand for veterinary anti-infectives in near future.
  • The antivirals segment is expected to showcase lucrative growth in the market for veterinary anti-infectives, as animals are susceptible to various viral infections, such as rabies and feline calicivirus among others. As recorded by WHO in 2019, humans are highly susceptible to contract rabies virus through a dog bite. It is recorded that up to 99% of cases, dogs are accountable for rabies transmission to humans. An awareness program; United Against Rabies Collaboration, involving four partners, namely, WHO, the Global Alliance for Rabies Control (GARC), the World Organisation for Animal Health (OIE), and the Food and Agriculture Organization of the United Nations (FAO), works toward Zero by 30—zero human rabies deaths by 2030.
  • Route of Administration Insights
  • The oral route of administration segment accounted for the largest market share in 2018 and is anticipated to witness the fastest growth during the forecast period, primarily owing to ease of use offered by this method. Moreover, incorporation of oral route of administration is beneficial to extend the duration of action as it limits the visits to hospitals and veterinary clinics. Tetracyclines, β lactams, aminoglycosides, diazepam, macrolides, and sulphonamides are some of the commonly used antimicrobials drugs.
  • Injectables held the second largest market share in 2018 as injectables help with good absorption of drugs, especially for the drugs with a low oral bioavailability along with quick onset action. Though, sometimes it may be difficult to administer an injection to animals. NSAIDs such as Ketoprofen and Metacam are some of the most commonly administered injectables.
  • Distribution Channel Insights
  • Retail pharmacies held the largest market share in 2018, attributed to easy distribution and availability of vaccines and medicines through retail pharmacies. Moreover, digitization of retail pharmacies to reduce the risk of errors in the prescriptions is anticipated to propel the segment growth in the forthcoming years.
  • The E-commerce segment is anticipated to witness exponential growth over the forecast period, attributed to increased convenience for patients unwilling to purchase medicines from retail or hospital pharmacies. Besides, an improved regulatory framework for animal products and consistent efforts by government authorities, such as the U.S. Food and Drug Administration (FDA) to eliminate counterfeit, expired, and adulterated products in online pharmacies are likely to present remunerative growth opportunities to this segment in near future.
  • Regional Insights
  • North America accounted for the largest revenue share in 2018. The presence of advanced animal healthcare programs coupled with awareness regarding animal health is projected to drive the regional market growth. For instance, the North American Pet Health Insurance Association focuses on promoting awareness of pet health insurance coverage and developing and exploring partnerships to address the challenges affecting the animal health industry. Moreover, rising disease prevalence in pets and livestock is further pushing the need for effective and quick treatment options which is anticipated to drive the regional demand for veterinary anti-infectives.
  • Latin America is expected to expand at a lucrative CAGR during the forecast period. The market is marked by high R&D investments by international players as well as consistent efforts for commercialization of veterinary pharmaceuticals and vaccines at relatively lower prices and by the foodborne disease outbreaks in countries like Brazil, Mexico, and Argentina.
  • KEY MARKET SEGMENTS
  • By Animal
  • Livestock
  • Poultry
  • Swine
  • Cattle
  • Sheep & Goats
  • Fish
  • Others
  • Companion animal
  • Dog
  • Cat
  • Others
  • By Product
  • Antibacterial
  • Cephalosporins
  • Tetracyclines
  • Penicillin
  • Macrolides
  • Others (Quinoles, sulfonamides, polymyxins)
  • Antifungals
  • Antivirals
  • Others
  • By Route of Administration
  • Oral
  • Injectables
  • Others
  • By Distribution Channel
  • Veterinary Clinics
  • Retail Pharmacies
  • E-commerce
  • By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
  • KEY MARKET SEGMENTS
  • Zoetis, Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale
  • Vetoquinol S.A.
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation

SkyQuest's Expertise:

The Veterinary Anti-infectives Market is being analyzed by SkyQuest's analysts with the help of 20+ scheduled Primary interviews from both the demand and supply sides. We have already invested more than 250 hours on this report and are still refining our date to provide authenticated data to your readers and clients. Exhaustive primary and secondary research is conducted to collect information on the market, peer market, and parent market.

Our cross-industry experts and revenue-impact consultants at SkyQuest enable our clients to convert market intelligence into actionable, quantifiable results through personalized engagement.

Scope Of Report

Report Attribute Details
The base year for estimation 2021
Historical data 2016 – 2022
Forecast period 2022 – 2028
Report coverage Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis
Segments covered
  • By Animal - Livestock, Poultry, Swine, Cattle, Sheep & Goats, Fish, Others, Companion animal, Dog, Cat, Others
  • By Product - Antibacterial, Cephalosporins, Tetracyclines, Penicillin, Macrolides, Others (Quinoles, sulfonamides, polymyxins), Antifungals, Antivirals, Others
  • By Route of Administration - Oral, Injectables, Others
  • By Distribution Channel - Veterinary Clinics, Retail Pharmacies, E-commerce
  • By Region - North America, Europe, Asia Pacific, Latin America, Middle East & Africa, KEY MARKET SEGMENTS, Zoetis, Inc., Boehringer Ingelheim GmbH, Ceva Santé Animale, Vetoquinol S.A., Merck & Co., Inc.
Regional scope North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
Country scope U.S., Canada, Germany, France, UK, Italy, Spain, China, India, Japan, Brazil, GCC Countries, South Africa
Key companies profiled
  • sights
  • The global veterinary anti-infectives market size was valued at USD 5.18 billion in 2018 and is expected to expand at a CAGR of 6.4% during the forecast period. The increasing awareness regarding better animal health is anticipated to drive the growth. According to a 2017 survey by the Centers for Disease Control and Prevention (CDC), approximately 48 million people get infected, 128,000 are hospitalized, and 3,000 die each year due to foodborne diseases in the U.S. Therefore, there is a rising need to curb these outbreaks with effective treatment which will further render an exponential growth for the market. Rising pressure on livestock owners to uphold the veterinary health standards to meet the demand for dairy products, fresh meat, dietary nutrition, and animal vaccines is anticipated to further speed up the adoption of veterinary anti-infectives in near future.
  • Rising pet adoption coupled with rising concerns regarding pet health and prevalence of bacterial infection, especially in dogs, is anticipated to further propel the market growth. Leptospirosis, staphylococcal infection, bacterial ear infection, actinomycosis, and nocardiosis are some of the most common forms of infections in pets. As per a report published by the Michigan Department of Agriculture and Rural Development 2018, 115 cases were recorded. Moreover, pets are susceptible to bacterial diseases, such as plague, brucellosis, and Lyme disease. According to the qualitative report by the CDC in 2018, cats are more prone to plague than dogs and can pass on the infection to humans as well.
  • The market players are investing in clinical trials of veterinary medicines, which is anticipated to bode well for the growth of the veterinary medicines market. For instance, Zoetis Inc. and Regeneron Pharmaceuticals, Inc. entered into a 5 years collaboration in June 2018, for monoclonal antibody therapeutics research to discover new animal health treatment. From this collaboration, Zoetis Inc. is licensed for Regeneron’s VelocImmune, an antibody technology for the development of monoclonal antibodies modified for species-specific use in livestock and companion animals.
  • Animal health insurance is also growing in line with the rise in livestock farming and the adoption of companion animals. Factors, such as increasing government efforts to prevent zoonosis and new product inventions are expected to exhibit a positive impact on market growth. For instance, in 2016, as per the European External Action Service (EEAS), the government invested USD 4.7 million in veterinary healthcare.
  • Animal Type Insights
  • Livestock accounted for the largest revenue share of the veterinary anti-infectives market in 2018. Livestock is sub-segmented into poultry, swine, cattle, sheep and goats, fish, and others. This segment is anticipated to witness significant growth owing to increasing meat consumption, growing daily needs, and environmental sustainability. As per the 2017 data by the North American Meat Institute, the poultry and meat industries are the largest division of the U.S. agriculture sector. This factor is anticipated to positively influence the livestock segment over the forecast period.
  • However, the companion animal segment is projected to register the fastest CAGR over the forecast period. Rising awareness regarding the health benefits associated with the adoption of small companion animals is anticipated to bode well for the growth of the segment. Some of these health benefits include decreased blood pressure, stress, anxiety, cholesterol levels, and increased psychological stability and opportunities for socialization. According to American Pet Products Association (APPA), National Pet Owners Survey 2017, households with children are three times more likely to adopt small animals as pets which leads to growing concerns as well as expenditure for veterinary healthcare needs.
  • Product Insights
  • Antibacterials segment accounted for the largest revenue share in the market for veterinary anti-infectives in 2018, owing to the rising prevalence of bacterial infections in livestock and companion animals. Major anti-bacterial, such as cephalosporins, tetracyclines, penicillins, macrolides, quinolones, sulfonamides, and polymyxins, are specifically developed for animals. The World Health Organization (WHO) engages in various activities to address health threats at the human-animal-ecosystem interface including antibacterial resistance, food-borne zoonoses, and food consumption. This is expected to drive the need for better healthcare facilities for vets and demand for veterinary anti-infectives in near future.
  • The antivirals segment is expected to showcase lucrative growth in the market for veterinary anti-infectives, as animals are susceptible to various viral infections, such as rabies and feline calicivirus among others. As recorded by WHO in 2019, humans are highly susceptible to contract rabies virus through a dog bite. It is recorded that up to 99% of cases, dogs are accountable for rabies transmission to humans. An awareness program; United Against Rabies Collaboration, involving four partners, namely, WHO, the Global Alliance for Rabies Control (GARC), the World Organisation for Animal Health (OIE), and the Food and Agriculture Organization of the United Nations (FAO), works toward Zero by 30—zero human rabies deaths by 2030.
  • Route of Administration Insights
  • The oral route of administration segment accounted for the largest market share in 2018 and is anticipated to witness the fastest growth during the forecast period, primarily owing to ease of use offered by this method. Moreover, incorporation of oral route of administration is beneficial to extend the duration of action as it limits the visits to hospitals and veterinary clinics. Tetracyclines, β lactams, aminoglycosides, diazepam, macrolides, and sulphonamides are some of the commonly used antimicrobials drugs.
  • Injectables held the second largest market share in 2018 as injectables help with good absorption of drugs, especially for the drugs with a low oral bioavailability along with quick onset action. Though, sometimes it may be difficult to administer an injection to animals. NSAIDs such as Ketoprofen and Metacam are some of the most commonly administered injectables.
  • Distribution Channel Insights
  • Retail pharmacies held the largest market share in 2018, attributed to easy distribution and availability of vaccines and medicines through retail pharmacies. Moreover, digitization of retail pharmacies to reduce the risk of errors in the prescriptions is anticipated to propel the segment growth in the forthcoming years.
  • The E-commerce segment is anticipated to witness exponential growth over the forecast period, attributed to increased convenience for patients unwilling to purchase medicines from retail or hospital pharmacies. Besides, an improved regulatory framework for animal products and consistent efforts by government authorities, such as the U.S. Food and Drug Administration (FDA) to eliminate counterfeit, expired, and adulterated products in online pharmacies are likely to present remunerative growth opportunities to this segment in near future.
  • Regional Insights
  • North America accounted for the largest revenue share in 2018. The presence of advanced animal healthcare programs coupled with awareness regarding animal health is projected to drive the regional market growth. For instance, the North American Pet Health Insurance Association focuses on promoting awareness of pet health insurance coverage and developing and exploring partnerships to address the challenges affecting the animal health industry. Moreover, rising disease prevalence in pets and livestock is further pushing the need for effective and quick treatment options which is anticipated to drive the regional demand for veterinary anti-infectives.
  • Latin America is expected to expand at a lucrative CAGR during the forecast period. The market is marked by high R&D investments by international players as well as consistent efforts for commercialization of veterinary pharmaceuticals and vaccines at relatively lower prices and by the foodborne disease outbreaks in countries like Brazil, Mexico, and Argentina.
  • KEY MARKET SEGMENTS
  • By Animal
  • Livestock
  • Poultry
  • Swine
  • Cattle
  • Sheep & Goats
  • Fish
  • Others
  • Companion animal
  • Dog
  • Cat
  • Others
  • By Product
  • Antibacterial
  • Cephalosporins
  • Tetracyclines
  • Penicillin
  • Macrolides
  • Others (Quinoles, sulfonamides, polymyxins)
  • Antifungals
  • Antivirals
  • Others
  • By Route of Administration
  • Oral
  • Injectables
  • Others
  • By Distribution Channel
  • Veterinary Clinics
  • Retail Pharmacies
  • E-commerce
  • By Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa
  • KEY MARKET SEGMENTS
  • Zoetis, Inc.
  • Boehringer Ingelheim GmbH
  • Ceva Santé Animale
  • Vetoquinol S.A.
  • Merck & Co., Inc.
  • Phibro Animal Health Corporation
Customization scope Free report customization (15% Free customization) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options Reap the benefits of customized purchase options to fit your specific research requirements.

Objectives of the Study

  • To forecast the market size, in terms of value, for various segments with respect to five main regions, namely, North America, Europe, Asia-Pacific (APAC), Latin America (LATAM), Middle East & Africa (MEA)
  • To provide detailed information regarding the major factors influencing the growth of the Market (drivers, restraints, opportunities, and challenges)
  • To strategically analyze the micro markets with respect to the individual growth trends, future prospects, and contribution to the total market
  • To provide a detailed overview of the value chain and analyze market trends with the Porter's five forces analysis
  • To analyze the opportunities in the market for various stakeholders by identifying the high-growth Segments
  • To identify the key players and comprehensively analyze their market position in terms of ranking and core competencies, along with detailing the competitive landscape for the market leaders
  • To analyze competitive development such as joint ventures, mergers and acquisitions, new product launches and development, and research and development in the market

What does this Report Deliver?

  • Market Estimation for 20+ Countries
  • Historical data coverage: 2016 to 2022
  • Growth projections: 2022 to 2028
  • SkyQuest's premium market insights: Innovation matrix, IP analysis, Production Analysis, Value chain analysis, Technological trends, and Trade analysis
  • Customization on Segments, Regions, and Company Profiles
  • 100+ tables, 150+ Figures, 10+ matrix
  • Global and Country Market Trends
  • Comprehensive Mapping of Industry Parameters
  • Attractive Investment Proposition
  • Competitive Strategies Adopted by Leading Market Participants
  • Market drivers, restraints, opportunities, and its impact on the market
  • Regulatory scenario, regional dynamics, and insights of leading countries in each region
  • Segment trends analysis, opportunity, and growth
  • Opportunity analysis by region and country
  • Porter's five force analysis to know the market's condition
  • Pricing analysis
  • Parent market analysis
  • Product portfolio benchmarking

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Veterinary Anti-infectives Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Veterinary Anti-infectives Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)
  • sights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The global veterinary anti-infectives market size was valued at USD 5.18 billion in 2018 and is expected to expand at a CAGR of 6.4% during the forecast period. The increasing awareness regarding better animal health is anticipated to drive the growth. According to a 2017 survey by the Centers for Disease Control and Prevention (CDC), approximately 48 million people get infected, 128,000 are hospitalized, and 3,000 die each year due to foodborne diseases in the U.S. Therefore, there is a rising need to curb these outbreaks with effective treatment which will further render an exponential growth for the market. Rising pressure on livestock owners to uphold the veterinary health standards to meet the demand for dairy products, fresh meat, dietary nutrition, and animal vaccines is anticipated to further speed up the adoption of veterinary anti-infectives in near future.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Rising pet adoption coupled with rising concerns regarding pet health and prevalence of bacterial infection, especially in dogs, is anticipated to further propel the market growth. Leptospirosis, staphylococcal infection, bacterial ear infection, actinomycosis, and nocardiosis are some of the most common forms of infections in pets. As per a report published by the Michigan Department of Agriculture and Rural Development 2018, 115 cases were recorded. Moreover, pets are susceptible to bacterial diseases, such as plague, brucellosis, and Lyme disease. According to the qualitative report by the CDC in 2018, cats are more prone to plague than dogs and can pass on the infection to humans as well.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The market players are investing in clinical trials of veterinary medicines, which is anticipated to bode well for the growth of the veterinary medicines market. For instance, Zoetis Inc. and Regeneron Pharmaceuticals, Inc. entered into a 5 years collaboration in June 2018, for monoclonal antibody therapeutics research to discover new animal health treatment. From this collaboration, Zoetis Inc. is licensed for Regeneron’s VelocImmune, an antibody technology for the development of monoclonal antibodies modified for species-specific use in livestock and companion animals.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Animal health insurance is also growing in line with the rise in livestock farming and the adoption of companion animals. Factors, such as increasing government efforts to prevent zoonosis and new product inventions are expected to exhibit a positive impact on market growth. For instance, in 2016, as per the European External Action Service (EEAS), the government invested USD 4.7 million in veterinary healthcare.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Animal Type Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Livestock accounted for the largest revenue share of the veterinary anti-infectives market in 2018. Livestock is sub-segmented into poultry, swine, cattle, sheep and goats, fish, and others. This segment is anticipated to witness significant growth owing to increasing meat consumption, growing daily needs, and environmental sustainability. As per the 2017 data by the North American Meat Institute, the poultry and meat industries are the largest division of the U.S. agriculture sector. This factor is anticipated to positively influence the livestock segment over the forecast period.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • However, the companion animal segment is projected to register the fastest CAGR over the forecast period. Rising awareness regarding the health benefits associated with the adoption of small companion animals is anticipated to bode well for the growth of the segment. Some of these health benefits include decreased blood pressure, stress, anxiety, cholesterol levels, and increased psychological stability and opportunities for socialization. According to American Pet Products Association (APPA), National Pet Owners Survey 2017, households with children are three times more likely to adopt small animals as pets which leads to growing concerns as well as expenditure for veterinary healthcare needs.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Product Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Antibacterials segment accounted for the largest revenue share in the market for veterinary anti-infectives in 2018, owing to the rising prevalence of bacterial infections in livestock and companion animals. Major anti-bacterial, such as cephalosporins, tetracyclines, penicillins, macrolides, quinolones, sulfonamides, and polymyxins, are specifically developed for animals. The World Health Organization (WHO) engages in various activities to address health threats at the human-animal-ecosystem interface including antibacterial resistance, food-borne zoonoses, and food consumption. This is expected to drive the need for better healthcare facilities for vets and demand for veterinary anti-infectives in near future.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The antivirals segment is expected to showcase lucrative growth in the market for veterinary anti-infectives, as animals are susceptible to various viral infections, such as rabies and feline calicivirus among others. As recorded by WHO in 2019, humans are highly susceptible to contract rabies virus through a dog bite. It is recorded that up to 99% of cases, dogs are accountable for rabies transmission to humans. An awareness program; United Against Rabies Collaboration, involving four partners, namely, WHO, the Global Alliance for Rabies Control (GARC), the World Organisation for Animal Health (OIE), and the Food and Agriculture Organization of the United Nations (FAO), works toward Zero by 30—zero human rabies deaths by 2030.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Route of Administration Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The oral route of administration segment accounted for the largest market share in 2018 and is anticipated to witness the fastest growth during the forecast period, primarily owing to ease of use offered by this method. Moreover, incorporation of oral route of administration is beneficial to extend the duration of action as it limits the visits to hospitals and veterinary clinics. Tetracyclines, β lactams, aminoglycosides, diazepam, macrolides, and sulphonamides are some of the commonly used antimicrobials drugs.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Injectables held the second largest market share in 2018 as injectables help with good absorption of drugs, especially for the drugs with a low oral bioavailability along with quick onset action. Though, sometimes it may be difficult to administer an injection to animals. NSAIDs such as Ketoprofen and Metacam are some of the most commonly administered injectables.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Distribution Channel Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Retail pharmacies held the largest market share in 2018, attributed to easy distribution and availability of vaccines and medicines through retail pharmacies. Moreover, digitization of retail pharmacies to reduce the risk of errors in the prescriptions is anticipated to propel the segment growth in the forthcoming years.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • The E-commerce segment is anticipated to witness exponential growth over the forecast period, attributed to increased convenience for patients unwilling to purchase medicines from retail or hospital pharmacies. Besides, an improved regulatory framework for animal products and consistent efforts by government authorities, such as the U.S. Food and Drug Administration (FDA) to eliminate counterfeit, expired, and adulterated products in online pharmacies are likely to present remunerative growth opportunities to this segment in near future.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Regional Insights
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America accounted for the largest revenue share in 2018. The presence of advanced animal healthcare programs coupled with awareness regarding animal health is projected to drive the regional market growth. For instance, the North American Pet Health Insurance Association focuses on promoting awareness of pet health insurance coverage and developing and exploring partnerships to address the challenges affecting the animal health industry. Moreover, rising disease prevalence in pets and livestock is further pushing the need for effective and quick treatment options which is anticipated to drive the regional demand for veterinary anti-infectives.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America is expected to expand at a lucrative CAGR during the forecast period. The market is marked by high R&D investments by international players as well as consistent efforts for commercialization of veterinary pharmaceuticals and vaccines at relatively lower prices and by the foodborne disease outbreaks in countries like Brazil, Mexico, and Argentina.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Animal
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Livestock
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Poultry
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Swine
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cattle
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Sheep & Goats
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Fish
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Companion animal
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Dog
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cat
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Product
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Antibacterial
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Cephalosporins
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Tetracyclines
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Penicillin
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Macrolides
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others (Quinoles, sulfonamides, polymyxins)
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Antifungals
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Antivirals
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Route of Administration
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Oral
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Injectables
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Others
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Distribution Channel
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Veterinary Clinics
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Retail Pharmacies
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • E-commerce
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • By Region
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • North America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Europe
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Asia Pacific
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Latin America
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Middle East & Africa
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • KEY MARKET SEGMENTS
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Zoetis, Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Boehringer Ingelheim GmbH
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Ceva Santé Animale
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Vetoquinol S.A.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Merck & Co., Inc.
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments
  • Phibro Animal Health Corporation
    • Exhibit Company Overview
    • Exhibit Business Segment Overview
    • Exhibit Financial Updates
    • Exhibit Key Developments

Methodology

For the Veterinary Anti-infectives Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Veterinary Anti-infectives Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Veterinary Anti-infectives Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Veterinary Anti-infectives Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

The global market for Veterinary Anti-infectives was estimated to be valued at US$ XX Mn in 2021.

The global Veterinary Anti-infectives Market is estimated to grow at a CAGR of XX% by 2028.

The global Veterinary Anti-infectives Market is segmented on the basis of Animal, Product, Route of Administration, Distribution Channel, Region.

Based on region, the global Veterinary Anti-infectives Market is segmented into North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

The key players operating in the global Veterinary Anti-infectives Market are sights, The global veterinary anti-infectives market size was valued at USD 5.18 billion in 2018 and is expected to expand at a CAGR of 6.4% during the forecast period. The increasing awareness regarding better animal health is anticipated to drive the growth. According to a 2017 survey by the Centers for Disease Control and Prevention (CDC), approximately 48 million people get infected, 128,000 are hospitalized, and 3,000 die each year due to foodborne diseases in the U.S. Therefore, there is a rising need to curb these outbreaks with effective treatment which will further render an exponential growth for the market. Rising pressure on livestock owners to uphold the veterinary health standards to meet the demand for dairy products, fresh meat, dietary nutrition, and animal vaccines is anticipated to further speed up the adoption of veterinary anti-infectives in near future., Rising pet adoption coupled with rising concerns regarding pet health and prevalence of bacterial infection, especially in dogs, is anticipated to further propel the market growth. Leptospirosis, staphylococcal infection, bacterial ear infection, actinomycosis, and nocardiosis are some of the most common forms of infections in pets. As per a report published by the Michigan Department of Agriculture and Rural Development 2018, 115 cases were recorded. Moreover, pets are susceptible to bacterial diseases, such as plague, brucellosis, and Lyme disease. According to the qualitative report by the CDC in 2018, cats are more prone to plague than dogs and can pass on the infection to humans as well., The market players are investing in clinical trials of veterinary medicines, which is anticipated to bode well for the growth of the veterinary medicines market. For instance, Zoetis Inc. and Regeneron Pharmaceuticals, Inc. entered into a 5 years collaboration in June 2018, for monoclonal antibody therapeutics research to discover new animal health treatment. From this collaboration, Zoetis Inc. is licensed for Regeneron’s VelocImmune, an antibody technology for the development of monoclonal antibodies modified for species-specific use in livestock and companion animals., Animal health insurance is also growing in line with the rise in livestock farming and the adoption of companion animals. Factors, such as increasing government efforts to prevent zoonosis and new product inventions are expected to exhibit a positive impact on market growth. For instance, in 2016, as per the European External Action Service (EEAS), the government invested USD 4.7 million in veterinary healthcare., Animal Type Insights, Livestock accounted for the largest revenue share of the veterinary anti-infectives market in 2018. Livestock is sub-segmented into poultry, swine, cattle, sheep and goats, fish, and others. This segment is anticipated to witness significant growth owing to increasing meat consumption, growing daily needs, and environmental sustainability. As per the 2017 data by the North American Meat Institute, the poultry and meat industries are the largest division of the U.S. agriculture sector. This factor is anticipated to positively influence the livestock segment over the forecast period., However, the companion animal segment is projected to register the fastest CAGR over the forecast period. Rising awareness regarding the health benefits associated with the adoption of small companion animals is anticipated to bode well for the growth of the segment. Some of these health benefits include decreased blood pressure, stress, anxiety, cholesterol levels, and increased psychological stability and opportunities for socialization. According to American Pet Products Association (APPA), National Pet Owners Survey 2017, households with children are three times more likely to adopt small animals as pets which leads to growing concerns as well as expenditure for veterinary healthcare needs., Product Insights, Antibacterials segment accounted for the largest revenue share in the market for veterinary anti-infectives in 2018, owing to the rising prevalence of bacterial infections in livestock and companion animals. Major anti-bacterial, such as cephalosporins, tetracyclines, penicillins, macrolides, quinolones, sulfonamides, and polymyxins, are specifically developed for animals. The World Health Organization (WHO) engages in various activities to address health threats at the human-animal-ecosystem interface including antibacterial resistance, food-borne zoonoses, and food consumption. This is expected to drive the need for better healthcare facilities for vets and demand for veterinary anti-infectives in near future., The antivirals segment is expected to showcase lucrative growth in the market for veterinary anti-infectives, as animals are susceptible to various viral infections, such as rabies and feline calicivirus among others. As recorded by WHO in 2019, humans are highly susceptible to contract rabies virus through a dog bite. It is recorded that up to 99% of cases, dogs are accountable for rabies transmission to humans. An awareness program; United Against Rabies Collaboration, involving four partners, namely, WHO, the Global Alliance for Rabies Control (GARC), the World Organisation for Animal Health (OIE), and the Food and Agriculture Organization of the United Nations (FAO), works toward Zero by 30—zero human rabies deaths by 2030., Route of Administration Insights, The oral route of administration segment accounted for the largest market share in 2018 and is anticipated to witness the fastest growth during the forecast period, primarily owing to ease of use offered by this method. Moreover, incorporation of oral route of administration is beneficial to extend the duration of action as it limits the visits to hospitals and veterinary clinics. Tetracyclines, β lactams, aminoglycosides, diazepam, macrolides, and sulphonamides are some of the commonly used antimicrobials drugs., Injectables held the second largest market share in 2018 as injectables help with good absorption of drugs, especially for the drugs with a low oral bioavailability along with quick onset action. Though, sometimes it may be difficult to administer an injection to animals. NSAIDs such as Ketoprofen and Metacam are some of the most commonly administered injectables., Distribution Channel Insights, Retail pharmacies held the largest market share in 2018, attributed to easy distribution and availability of vaccines and medicines through retail pharmacies. Moreover, digitization of retail pharmacies to reduce the risk of errors in the prescriptions is anticipated to propel the segment growth in the forthcoming years., The E-commerce segment is anticipated to witness exponential growth over the forecast period, attributed to increased convenience for patients unwilling to purchase medicines from retail or hospital pharmacies. Besides, an improved regulatory framework for animal products and consistent efforts by government authorities, such as the U.S. Food and Drug Administration (FDA) to eliminate counterfeit, expired, and adulterated products in online pharmacies are likely to present remunerative growth opportunities to this segment in near future., Regional Insights, North America accounted for the largest revenue share in 2018. The presence of advanced animal healthcare programs coupled with awareness regarding animal health is projected to drive the regional market growth. For instance, the North American Pet Health Insurance Association focuses on promoting awareness of pet health insurance coverage and developing and exploring partnerships to address the challenges affecting the animal health industry. Moreover, rising disease prevalence in pets and livestock is further pushing the need for effective and quick treatment options which is anticipated to drive the regional demand for veterinary anti-infectives., Latin America is expected to expand at a lucrative CAGR during the forecast period. The market is marked by high R&D investments by international players as well as consistent efforts for commercialization of veterinary pharmaceuticals and vaccines at relatively lower prices and by the foodborne disease outbreaks in countries like Brazil, Mexico, and Argentina., KEY MARKET SEGMENTS, By Animal, Livestock, Poultry, Swine, Cattle, Sheep & Goats, Fish, Others, Companion animal, Dog, Cat, Others, By Product , Antibacterial, Cephalosporins, Tetracyclines, Penicillin, Macrolides, Others (Quinoles, sulfonamides, polymyxins), Antifungals, Antivirals, Others, By Route of Administration , Oral, Injectables, Others, By Distribution Channel , Veterinary Clinics, Retail Pharmacies, E-commerce, By Region , North America, Europe, Asia Pacific, Latin America, Middle East & Africa, KEY MARKET SEGMENTS, Zoetis, Inc., Boehringer Ingelheim GmbH, Ceva Santé Animale, Vetoquinol S.A., Merck & Co., Inc., Phibro Animal Health Corporation.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Veterinary Anti-infectives Market

Product ID: UCMIG35I2209

$5,300
BUY NOW GET FREE SAMPLE